We investigated the histopathological, immunological, molecular, and clinical characteristics of UPK2-positive CRCs.<h4>Results</h4>UPK2 was expressed in 12% of CRCs and associated with adverse features including advanced stage, lymphovascular invasion, tumor budding, and micropapillary growth (p < 0.01). This evidence concerns the gene UPK2 and neoplasm.